Table-1.
S. No | Source of exosomes |
Exosomal content |
Outcome | Reference |
---|---|---|---|---|
1 | Rat Cardiac Fibroblasts | miR-21 | Cardiomyocyte hypertrophy | (13) |
2 | Rat cardiac progenitor cells | miR-15b, miR-17, miR-20a, miR-103, miR-199a, miR-210, miR-292 | Improved cardiac function and reduced fibrosis | (15) |
3 | Human serum | P53 responsive miRNA | Predictive biomarker for heart failure | (27) |
4 | Human cardiac progenitor cells | miR-210, miR-132, and miR-146a-3p | Reduced apoptosis, enhanced angiogenesis and improved left ventricular ejection fraction | (30) |
5 | Human Cardiosphere derived cells | miR-146a | Reduced apoptosis, enhanced angiogenesis and promoted cardiomyocyte regeneration | (31) |
6 | Human Endothelial cells | miR-126 | Promote vascular endothelial repair | (44) |
7 | Mouse EC | miR-503 | miR-503 regulates pericyte-endothelial crosstalk in microvascular diabetic complications | (47) |
8 | Embryonic stem cells | miR-294 | Reduced apoptosis, enhanced angiogenesis and cardiac progenitor cell activation and cardiomyocyte proliferation | (50) |
9 | Human Mesenchymal stem cells | Protein | Preserved cardiac function and reduced infarct size post cardiac ischemia/reperfusion injury | (51) |
10 | Mouse model of sepsis | Not applicable | Blockade of exosome generation in sepsis dampens the sepsis-triggered inflammatory response and thereby, improves cardiac function and survival. | (54) |